Veracyte Inc [VCYT] stock is trading at $42.93, down -2.01%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The VCYT shares have gain 5.79% over the last week, with a monthly amount glided 4.73%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Veracyte Inc [NASDAQ: VCYT] stock has seen the most recent analyst activity on December 05, 2024, when Goldman downgraded its rating to a Neutral and also revised its price target to $37 from $38. Previously, Wolfe Research started tracking the stock with Outperform rating on November 15, 2024, and set its price target to $50. On October 16, 2024, UBS initiated with a Buy rating and assigned a price target of $43 on the stock. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $40 on October 10, 2024. Needham reiterated its recommendation of a Buy and raised its price target to $33 on February 23, 2024. Raymond James downgraded its rating to Mkt Perform for this stock on January 18, 2023. In a note dated January 05, 2023, Scotiabank initiated an Sector Outperform rating and provided a target price of $33 on this stock.
Veracyte Inc [VCYT] stock has fluctuated between $18.61 and $46.00 over the past year. Currently, Wall Street analysts expect the stock to reach $35 within the next 12 months. Veracyte Inc [NASDAQ: VCYT] shares were valued at $42.93 at the most recent close of the market. An investor can expect a potential drop of -18.47% based on the average VCYT price forecast.
Analyzing the VCYT fundamentals
Veracyte Inc [NASDAQ:VCYT] reported sales of 425.33M for the trailing twelve months, which represents a growth of 28.58%. Gross Profit Margin for this corporation currently stands at 0.65% with Operating Profit Margin at 0.03%, Pretax Profit Margin comes in at -0.02%, and Net Profit Margin reading is -0.02%. To continue investigating profitability, this company’s Return on Assets is posted at -0.01, Equity is -0.01 and Total Capital is 0.01. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 42.12 points at the first support level, and at 41.31 for the second support level. However, for the 1st resistance point, the stock is sitting at 43.62, and for the 2nd resistance point, it is at 44.31.
Ratios To Look Out For
For context, Veracyte Inc’s Current Ratio is 5.08. As well, the Quick Ratio is 4.79, while the Cash Ratio is 3.9. Considering the valuation of this stock, the price to sales ratio is 7.82, the price to book ratio is 2.83.
Transactions by insiders
Recent insider trading involved EASTHAM KARIN, Director, that happened on Jan 02 ’25 when 10000.0 shares were sold. Director, KARIN EASTHAM completed a deal on Jan 02 ’25 to buy 10000.0 shares. Meanwhile, Chief Executive Officer Stapley Marc sold 5590.0 shares on Dec 13 ’24.
